Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of “Hold” from Analysts

Qiagen N.V. (NYSE:QGEN) has earned a consensus recommendation of “Hold” from the fourteen analysts that are currently covering the company, MarketBeat reports. Nine equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokerages that have covered the stock in the last year is $43.9250.

A number of equities research analysts have commented on the company. Citigroup reissued a “neutral” rating and issued a $45.00 price objective (up from $38.00) on shares of Qiagen in a research note on Monday, August 10th. Morgan Stanley raised shares of Qiagen from an “overweight” rating to an “overweight” rating and lifted their price target for the company from $40.00 to $42.00 in a research report on Tuesday, June 23rd. Stifel Nicolaus set a $40.00 price target on shares of Qiagen in a research note on Friday, August 7th. TD Cowen restated a “hold” rating on shares of Qiagen in a report on Wednesday, July 15th. Finally, Kepler Capital Markets set a $38.60 price objective on shares of Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th.

Qiagen Price Performance

Shares of QGEN opened at $43.35 on Tuesday. The business has a 50-day moving average of $41.51 and a 200-day moving average of $40.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.85 and a quick ratio of 2.31. The company has a market capitalization of $8.93 billion, a price-to-earnings ratio of 22.21, a price-to-earnings-growth ratio of 4.29 and a beta of 0.63. Qiagen has a 1 year low of $32.53 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The business had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same quarter last year, the firm earned $0.60 earnings per share. Qiagen’s quarterly revenue was up .2% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, equities research analysts anticipate that Qiagen will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Institutional investors and hedge funds have recently bought and sold shares of the stock. Banque Cantonale Vaudoise lifted its stake in Qiagen by 1.8% during the 4th quarter. Banque Cantonale Vaudoise now owns 16,363 shares of the company’s stock valued at $747,000 after acquiring an additional 290 shares in the last quarter. Commerce Bank lifted its position in shares of Qiagen by 4.9% during the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock valued at $302,000 after purchasing an additional 314 shares in the last quarter. Truist Financial Corp lifted its position in shares of Qiagen by 4.1% during the fourth quarter. Truist Financial Corp now owns 8,421 shares of the company’s stock valued at $379,000 after purchasing an additional 331 shares in the last quarter. Private Advisor Group LLC boosted its holdings in Qiagen by 7.1% during the third quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after purchasing an additional 378 shares during the last quarter. Finally, Farther Finance Advisors LLC boosted its holdings in Qiagen by 45.6% during the fourth quarter. Farther Finance Advisors LLC now owns 1,730 shares of the company’s stock worth $78,000 after purchasing an additional 542 shares during the last quarter. 70.00% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.